Integra LifeSciences (NASDAQ:IART) Issues Q4 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its fourth quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.81-0.89 for the period, compared to the consensus estimate of $0.87. The company issued revenue guidance of $441-451 million, compared to the consensus revenue estimate of $448.48 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.490 EPS.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock traded up $1.06 during trading hours on Wednesday, reaching $25.97. The company had a trading volume of 261,435 shares, compared to its average volume of 1,098,115. Integra LifeSciences has a one year low of $16.81 and a one year high of $45.42. The business has a fifty day simple moving average of $18.77 and a 200 day simple moving average of $24.38. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. The firm has a market cap of $2.01 billion, a PE ratio of 85.90, a price-to-earnings-growth ratio of 0.66 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02. The company had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. Integra LifeSciences’s revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.76 earnings per share. On average, analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Morgan Stanley increased their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Bank of America decreased their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday. Finally, Truist Financial cut their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $27.25.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.